MONTREAL, QUEBEC--(CCNMatthews - June 5, 2006) - Interim Data From HDAC Inhibitor, MGCD0103, Includes Three Leukemia Patients Exhibiting Complete Bone Marrow Responses. MethylGene Inc. (TSX:MYG) today announced interim data for its lead oncology product candidate, MGCD0103, an oral, non-hydroxamate, isotype-selective histone deacetylase (HDAC) inhibitor at the American Society of Clinical Oncology (ASCO) 2006 Annual Meeting held in Atlanta. The interim data was presented on two studies evaluating MGCD0103 in leukemia / myelodysplastic patients and in solid tumors. Of particular interest, three of nine evaluable patients, at the two highest doses, achieved a complete bone marrow response in a Leukemia / Myelodysplastic Syndrome (MDS) trial. In a separate solid tumor study, five patients experienced stable disease.
